Cargando…
Signal-Targeted Therapies and Resistance Mechanisms in Pancreatic Cancer: Future Developments Reside in Proteomics
For patients with metastatic pancreatic cancer that are not eligible for surgery, signal-targeted therapies have so far failed to significantly improve survival. These therapeutic options have been tested in phase II/III clinical trials mostly in combination with the reference treatment gemcitabine....
Autores principales: | Cintas, Célia, Douché, Thibaut, Therville, Nicole, Arcucci, Silvia, Ramos-Delgado, Fernanda, Basset, Céline, Thibault, Benoît, Guillermet-Guibert, Julie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6025626/ https://www.ncbi.nlm.nih.gov/pubmed/29865155 http://dx.doi.org/10.3390/cancers10060174 |
Ejemplares similares
-
Experimental pancreatic cancer develops in soft pancreas: novel leads for an individualized diagnosis by ultrafast elasticity imaging
por: Therville, Nicole, et al.
Publicado: (2019) -
Pancreatic cancer intrinsic PI3Kα activity accelerates metastasis and rewires macrophage component
por: Thibault, Benoit, et al.
Publicado: (2021) -
Targeting Class I-II-III PI3Ks in Cancer Therapy: Recent Advances in Tumor Biology and Preclinical Research
por: Thibault, Benoît, et al.
Publicado: (2023) -
Heterogeneity of Phosphatidylinositol-3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin Activation in Cancer: Is PI3K Isoform Specificity Important?
por: Cintas, Célia, et al.
Publicado: (2018) -
Transducing compressive forces into cellular outputs in cancer and beyond
por: Schmitter, Céline, et al.
Publicado: (2023)